Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study of Finasteride/tadalafil in patients with benign prostatic hyperplasia

Next Previous
Search
Trial Profile

Study of Finasteride/tadalafil in patients with benign prostatic hyperplasia

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 02 Aug 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Finasteride/tadalafil (Primary)
  • Indications Benign prostatic hyperplasia
  • Focus Adverse reactions

    • Most Recent Events

    • 02 Aug 2023 New trial record
    • 31 Jul 2023 According to a Blue Water Biotech Media Release, ENTADFI has received FDA approval for the indication of initiating treatment of the signs and symptoms of BPH in men with an enlarged prostate for up to 26 weeks.
    • 31 Jul 2023 According to a Blue Water Biotech Media Release, the company purchased ENTADFI in April 2023, followed by an asset purchase agreement for six FDA-approved assets, including ZONTIVITY, that is expected to close later this year.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top